Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat diet-Reference-Cited by-同舟云学术

Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat diet

Published:2020-11 Issue:11 Volume:6 Page:e05431
ISSN:2405-8440
Container-title:Heliyon
language:en
Short-container-title:Heliyon

Author:

Horikawa Tsuyoshi,Kawanami Takako,Hamaguchi Yuriko,Tanaka Yuki,Kita Shotaro,Ryorin Ryutaro,Takashi Yuichi^ORCID,Takahashi Hiroyuki,Tanabe Makito,Yanase Toshihiko,Kawanami Daiji^ORCID,Nomiyama Takashi

Funder

Kowa Company

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference30 articles.

1. Cardiovascular outcome trials of the newer anti-diabetic medications;Acharya;Prog. Cardiovasc. Dis.,2019

2. Diabetes is still risk for restenosis after drug-eluting stent in coronary arteries;Scheen;Diabetes Care,2004

3. Mouse model of femoral artery denudation injury associated with the rapid accumulation of adhesion molecules on the luminal surface and recruitment of neutrophils;Roque;Arterioscler. Thromb. Vasc. Biol.,2000

4. Smooth muscle cell-driven vascular diseases and molecular mechanisms of VSMC plasticity;Frismantiene;Cell. Signal.,2018

5. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury;Goto;Biochem. Biophys. Res. Commun.,2011

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An insight to treat cardiovascular diseases through phytochemicals targeting PPAR-α;Molecular and Cellular Biochemistry;2023-05-12

2. Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis;Metabolites;2023-05-02

3. Development of Heterocyclic PPAR Ligands for Potential Therapeutic Applications;Pharmaceutics;2022-10-08

4. Retinal degeneration induced in a mouse model of ischemia–reperfusion injury and its management by pemafibrate treatment;The FASEB Journal;2022-08-15

5. Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice;Biomedicines;2022-07-11